As Previously Reported was Allogene Therapeutics’s largest revenue line in fiscal 2022, bringing in $243.00K of $156.00K (156%).
| Revision of Prior Period | FY 2021 | FY 2022 |
|---|---|---|
| Restatement Adjustment | $75.60M | -$87.00K |
| As Previously Reported | $38.49M | $243.00K |
| Total | $114.09M | $156.00K |
Allogene Therapeutics brought in $156.00K from its two revenue lines in fiscal 2022, the year ended December 31, 2022. That was down 99.9% from $114.09M in fiscal 2021. As Previously Reported was the largest at $243.00K (155.8%).
The total is net of Restatement Adjustment, which took $87.00K off revenue in fiscal 2022.
Allogene Therapeutics (ALLO) reports its revenue by revision of prior period. In fiscal 2022, As Previously Reported was its largest revenue line, bringing in $243.00K (155.8% of the total).
As Previously Reported was Allogene Therapeutics' largest revenue line in fiscal 2022, bringing in $243.00K, or 155.8% of the $156.00K total across its two revenue lines.
Every figure comes from Allogene Therapeutics' annual financial filings, as reported. Each line keeps the name Allogene Therapeutics gives it, and years follow its fiscal calendar.
Allogene Therapeutics' revenue by revision of prior period goes back to fiscal 2021, with figures through fiscal 2022. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.